Positron emission tomography (PET) has emerged as a significant and promising imaging modality in pulmonary medicine over the past few years. Using D-glucose analogue 2-fluoro(fluorine-18)-2-deoxy-D-glucose (FDG) as an uptake contrast, the glucose metabolism of different lesions in the lung can be visualized and analyzed. Such imaging is of great value in differentiating benign and malignant pulmonary lesions. We conducted a prospective study to evaluate the efficacy of FDG-PET in our center. We enrolled 20 patients over a period of ten months. PET was performed on all of these patients for suspected malignant lung lesions. Our experience showed that PET performed well in differentiating a lesion, with an overall sensitivity of 75% and specificity of 100%, using pathology obtained by biopsy or surgery as the gold standard. The positive predictive value and negative predictive value were 100% and 50%, respectively. It is our conclusion that PET cannot fully replace invasive procedures for tumor detection, based on the low negative predictive value seen in our analysis. However, large-scale studies may still be needed to further evaluate the accuracy and efficacy of PET in the diagnosis of pulmonary nodules in Taiwan.